Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer
Clinical trial NCT05654532 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05654532
- Sponsor
- Accutar Biotechnology Inc
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-29
- Primary completion
- 2026-03-31
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.